NHS & getting help: The Full Evidence

What are the NHS referral criteria for specialist allergy services?

What the research says

NHS referral criteria for specialist allergy services are not uniformly codified at a national level but are guided primarily by NICE guidelines (notably CG134 for anaphylaxis) and local trust protocols, with referral indicated for severe or complex cases including anaphylaxis, venom allergy, drug hypersensitivity, recurrent angioedema, and rhinitis or urticaria resistant to maximal primary care therapy. For allergic rhinitis specifically, referral to specialist allergy services is reserved for cases unresponsive to first-line treatments such as antihistamines and intranasal corticosteroids, distinguishing it from higher-acuity conditions like anaphylaxis where any occurrence triggers referral. The evidence consistently highlights chronic underprovision of NHS specialist allergy services, with access remaining geographically inequitable and demand substantially exceeding capacity.

How it works

Referral thresholds are clinically risk-stratified: conditions involving systemic immune-mediated reactions (IgE-mediated anaphylaxis, C1-inhibitor deficiency) warrant urgent specialist input for definitive diagnosis, allergen immunotherapy candidacy, and adrenaline auto-injector provision, whereas rhinitis management is stepwise, escalating to specialist care only when empirical pharmacotherapy has failed and quality of life or diagnostic uncertainty justifies resource use.

---

Which hayfever treatments are available over the counter vs prescription in the UK?

What the research says

In the UK, a broad range of hay fever treatments are available over the counter (OTC), including second-generation oral antihistamines (cetirizine, loratadine, fexofenadine 120mg), intranasal corticosteroids (fluticasone propionate, beclometasone, mometasone furoate nasal sprays), sodium cromoglicate eye drops, and short-term decongestant nasal sprays. Prescription-only treatments include azelastine nasal spray, combination products (e.g., azelastine plus fluticasone propionate), higher-strength formulations, and specialist-administered immunotherapy (sublingual or subcutaneous). NHS England guidance advises GPs against routinely prescribing OTC-available treatments on the NHS for adults, reflecting a policy shift toward self-care for mild-to-moderate disease.

How it works

Intranasal corticosteroids reduce local eosinophilic inflammation and mast cell activity in nasal mucosa, making them the most effective single-agent treatment for nasal symptoms, while antihistamines competitively block H1 receptors to reduce histamine-mediated symptoms; immunotherapy uniquely modifies the underlying Th2-skewed immune response through allergen desensitisation, which is why it remains in specialist hands.

---

How do UK patients access immunotherapy on the NHS?

What the research says

UK NHS patients access allergen immunotherapy (AIT) for allergic rhinitis via GP referral to specialist allergy clinics following demonstrated failure of stepwise pharmacotherapy (intranasal corticosteroids, antihistamines, leukotriene antagonists), with eligibility requiring confirmed sensitisation via SPT or specific IgE. Both SCIT and SLIT are available on the NHS, with NICE-approved SLIT products (e.g., Grazax, Acarizax, Itulazax) prescribable in allergy clinics and SCIT delivered in hospital settings with resuscitation facilities. However, access is significantly inequitable, with commissioning devolved to individual ICBs, resulting in substantial geographic variation in service availability.

How it works

AIT modifies the underlying allergic immune response by inducing allergen-specific tolerance, shifting the Th2-dominant response and increasing regulatory T-cell activity, thereby reducing symptoms and altering disease course rather than merely suppressing them. This disease-modifying effect justifies the 3-year treatment commitment and specialist oversight required for safe administration.